ENDRA Life Sciences (NASDAQ:NDRA) and SONOVA HLDG AG/ADR (OTCMKTS:SONVY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Institutional and Insider Ownership
13.3% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 0.3% of SONOVA HLDG AG/ADR shares are held by institutional investors. 11.4% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
SONOVA HLDG AG/ADR pays an annual dividend of $0.33 per share and has a dividend yield of 0.7%. ENDRA Life Sciences does not pay a dividend. SONOVA HLDG AG/ADR pays out 23.1% of its earnings in the form of a dividend.
Valuation and Earnings
This table compares ENDRA Life Sciences and SONOVA HLDG AG/ADR’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ENDRA Life Sciences||$10,000.00||759.22||-$9.80 million||($2.10)||-0.48|
|SONOVA HLDG AG/ADR||$2.79 billion||5.14||$458.51 million||$1.43||31.14|
SONOVA HLDG AG/ADR has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than SONOVA HLDG AG/ADR, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations and price targets for ENDRA Life Sciences and SONOVA HLDG AG/ADR, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ENDRA Life Sciences||0||0||3||0||3.00|
|SONOVA HLDG AG/ADR||1||0||2||0||2.33|
ENDRA Life Sciences presently has a consensus target price of $6.00, indicating a potential upside of 494.06%. Given ENDRA Life Sciences’ stronger consensus rating and higher possible upside, research analysts plainly believe ENDRA Life Sciences is more favorable than SONOVA HLDG AG/ADR.
This table compares ENDRA Life Sciences and SONOVA HLDG AG/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ENDRA Life Sciences||N/A||-327.27%||-232.79%|
|SONOVA HLDG AG/ADR||N/A||N/A||N/A|
Volatility & Risk
ENDRA Life Sciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, SONOVA HLDG AG/ADR has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.
ENDRA Life Sciences beats SONOVA HLDG AG/ADR on 8 of the 15 factors compared between the two stocks.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
SONOVA HLDG AG/ADR Company Profile
Sonova Holding AG designs, develops, manufactures, and distributes hearing systems for adults and children with hearing impairment. It offers hearing instruments, cochlear implants, wireless communication products, and rechargeable hearing aids, as well as professional audiological care services. The company provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; and professional hearing care services under the AudioNova, Audium, AuditionSanté, Boots Hearingcare, Connect Hearing, Fiebing, Geers, Hansaton, Lapperre, Lindacher, Schoonenberg, Triton, and Vitakustik brands. Sonova Holding operates through sales channels, including independent healthcare professionals, government agencies, clinics, and retail network, as well as through Sonova-owned wholesale companies and independent distributors. It operates in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.